Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
Open accessThe DOI matches its Crossref record.
Abstract
Abstract Background Effective therapies for pts with treatment-refractory mCRPC are an important unmet medical need. Niraparib is a highly selective poly ADP-ribose polymerase (PARP) inhibitor of PARP-1 and PARP-2 DNA-repair polymerases. Methods GALAHAD is an ongoing open-label phase II study assessing niraparib (300 mg daily) in pts with mCRPC and DRD with disease progression on taxane and androgen receptor-targeted therapy. DRD status was evaluated by a plasma or tissue-based test and defined as having biallelic alterations in BRCA1/2 (BRCA), ATM, FANCA, PALB2, CHEK2, BRIP1, or HDAC2. Primary endpoint was objective response rate (ORR) by RECIST 1.1 with no evidence of bone progression as per the PCWG3 criteria. Composite response rate (CRR) was defined as ORR, conversion of circulating tumor cells to Results As of 23 May 2019, 165 pts were enrolled, of whom 81 had biallelic DRD (46 BRCA and 35 non-BRCA) and had a minimum of 16 weeks of follow up. 51/81 had measurable disease at baseline (29 BRCA and 22 non-BRCA); 47% of pts had visceral metastases. Median follow-up in BRCA and non-BRCA was 7.3 and 6.4 mo, respectively. In BRCA, ORR was 41% and CRR was 63% (table); median duration of objective response was 5.5 mo (range: 3.5–9.2). 7/12 BRCA responses were ongoing. Median rPFS and OS in BRCA were 8.2 and 12.6 mo, respectively. In non-BRCA, objective response was noted in 2/22 pts (both had FANCA) and CRR was 17%; durations of objective response were 3.8 and 6.5 mo, respectively. Grade 3/4 treatment-emergent adverse events were mostly hematologic—anemia (29%), thrombocytopenia (15%) and neutropenia (7%)—and managed with dose interruption or modification. Conclusions Niraparib demonstrates clinical activity in pts with treatment-refractory mCRPC with durable responses particularly in biallelic BRCA mutation carriers. Table . LBA50 All biallelic DRD (n = 81) Response BRCA1/2 Non-BRCA n (%) (95% CI) (n = 46) (n = 35) Objective RR 12/29 (41) (23.5, 61.1) 2/22 (9) (1.1, 29.2) PSA50 23/46 (50) (34.9, 65.1) 1/35 (3) (0.1, 14.9) CTC Conversion 18/38 (47) (31.0, 64.2) 5/24 (21) (7.1, 42.2) CRR 29/46 (63) (47.6, 76.8) 6/35 (17) (6.6, 33.7) Median rPFS, mo (95% CI) 8.2 (5.2, 11.1) 5.3 (1.9, 5.7) Median OS, mo (95% CI) 12.6 (9.2, 15.7) 14.0 (5.3, 20.1) CI, confidence interval; CRR, composite response rate; CTC, circulating tumor cells; DRD, DNA-repair gene defects; ORR, objective response rate; OS, overall survival; PSA50, ≥50% decline in prostate-specific antigen; rPFS, radiographic progression-free survival. Clinical trial identification NCT02854436. Editorial acknowledgement Writing assistance was provided by Ramji Narayanan of SIRO Clinpharm Pvt Ltd and funded by Janssen Global Services, LLC. Legal entity responsible for the study Janssen Research & Development, LLC. Funding Janssen Research & Development, LLC. Disclosure S.K. Sandhu: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Speaker Bureau / Expert testimony: Bristol-Myers Squibb; Honoraria (self), Speaker Bureau / Expert testimony: Merck. W.K. Kelly: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Sanofi; Research grant / Funding (institution): Janssen; Research grant / Funding (institution): Novartis. H.I. Scher: Leadership role, Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options: Asterias Biotherapeutics; Advisory / Consultancy: Ambry Genetics Corporation; Advisory / Consultancy: Konica Minolta,Inc; Advisory / Consultancy: Janssen Biotech, Inc; Advisory / Consultancy, Research grant / Funding (institution): Janssen Research & Development; Advisory / Consultancy, Travel / Accommodation / Expenses: OncLive Insights; Advisory / Consultancy: Physician Education Resource; Advisory / Consultancy, Travel / Accommodation / Expenses: Sanofi; Advisory / Consultancy, Travel / Accommodation / Expenses: WIRB-Copernicus Group; Research grant / Funding (institution): Illumina ; Research grant / Funding (institution): Innocrin Pharma; Travel / Accommodation / Expenses: Physician Education Resource. E. Efstathiou: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): Janssen-Cilag; Honoraria (self), Research grant / Funding (institution): Sanofi; Honoraria (self), Advisory / Consultancy: Takeda; Advisory / Consultancy, Research grant / Funding (institution): Astellas Pharma; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Innocrin Pharma; Advisory / Consultancy: MSD; Advisory / Consultancy: Tolmar. P.N. Lara: Honoraria (self), Advisory / Consultancy: Pfizer; Advisory / Consultancy: AbbVie; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Bayer; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: CellMax Life; Advisory / Consultancy: Exelixis; Advisory / Consultancy: Foundation Medicine; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Nektar; Advisory / Consultancy: Turnstone Bio; Research grant / Funding (institution): Aragon Pharmaceuticals; Research grant / Funding (institution): Genentech ; Research grant / Funding (institution): GlaxoSmithKline ; Research grant / Funding (institution): Heat Biologics; Research grant / Funding (institution): Incyte ; Research grant / Funding (institution): Janssen Biotech; Research grant / Funding (institution): Millennium, Pharmacyclics, Polaris,TRACON Pharma . E.Y. Yu: Advisory / Consultancy: Amgen; AstraZeneca; Bayer; Churchill Pharmaceuticals; EMD Serono; Incyte; Janssen; Merck; QED; Tolmar; Research grant / Funding (institution): Agensys; Astellas Pharma; Bayer; Dendreon; Genentech/Roche; Merck; Seattle Genetics. D.J. George: Honoraria (self): Bayer; Exelixis; Sanofi; Advisory / Consultancy: Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi; Speaker Bureau / Expert testimony: Bayer; Exelixis; Sanofi; Research grant / Funding (institution): Acerta Pharma ; Astellas Pharma ; Bayer ; Bristol-Myers Squibb ; Dendreon ; Exelixis ; Innocrin Pharma ; Janssen Oncology ; Novartis ; Pfizer ; Travel / Accommodation / Expenses: Bayer; Exelixis; Merck; Pfizer; Sanofi. K.N. Chi: Honoraria (self): Astellas Pharma; Bayer; Janssen; Sanofi; Advisory / Consultancy: Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi; Research grant / Funding (institution): Astellas Pharma ; Bayer ; Bristol-Myers Squibb ; Janssen ; Lilly/ImClone ; Merck ; Roche ; Sanofi ; Tokai Pharmaceuticals . F. Saad: Honoraria (self): Astellas Pharma; AstraZeneca; Bayer; Janssen Oncology; Sanofi; Advisory / Consultancy: Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Sanofi; Research grant / Funding (institution): Astellas Pharma ; AstraZeneca ; Bayer ; Janssen Oncology ; Sanofi . J. Summa: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. J.M. Freedman: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. G.E. Mason: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. E. Zhu: Full / Part-time employment: Janssen. D. Ricci: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. J.S. Simon: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. S. Cheng: Shareholder / Stockholder / Stock options, Full / Part-time employment: Janssen. All other authors have declared no conflicts of interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Abida, W., Patnaik, A., Campbell, D., Shapiro, J., Bryce, A. H., McDermott, R., Sautois, B., Vogelzang, N. J., Bambury, R. M., Voog, E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01035 · Cited by 694
Self-citationAbida, W., Campbell, D., Patnaik, A., Shapiro, J. D., Sautois, B., Vogelzang, N. J., Voog, E. G., Bryce, A. H., McDermott, R., Ricci, F., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0394 · Cited by 383
Self-citationTherapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Vikas, P., Borcherding, N., Chennamadhavuni, A., & Garje, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00570 · Cited by 179
“The efficacy of niraparib in patients with mCRPC after prior novel hormonal agent and chemotherapy was evaluated in the GALAHAD clinical trial (56).”
BackgroundMaurice Dror, C., Chi, K. N., & Khalaf, D. J. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1341 · Cited by 14
Self-citation
Metadata
- Authors
- Smith, M. R., Sandhu, S. K., Kelly, W. K., Scher, H. I., Efstathiou, E., Lara, P. N., Yu, E. Y., George, D. J., Chi, K. N., Saad, F., Summa, J., Freedman, J. M., Mason, G. E., Zhu, E., Ricci, D., Simon, J. S., Cheng, S., & Fizazi, K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 30
- Pages
- v884-v885
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2977585001
- Cited by
- 93
- References
- 0
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). https://app.cochat.ai/papers/10.1093/annonc/mdz394.043
- The paper
- Smith, M. R., Sandhu, S. K., Kelly, W. K., Scher, H. I., Efstathiou, E., Lara, P. N., Yu, E. Y., George, D. J., Chi, K. N., Saad, F., Summa, J., Freedman, J. M., Mason, G. E., Zhu, E., Ricci, D., Simon, J. S., Cheng, S., & Fizazi, K. (2019). Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Annals of Oncology. https://doi.org/10.1093/annonc/mdz394.043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.